Sana Biotechnology (NASDAQ:SANA) Shares Gap Up – Time to Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $3.21, but opened at $3.99. Sana Biotechnology shares last traded at $3.6460, with a volume of 8,137,808 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SANA. HC Wainwright decreased their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Morgan Stanley reissued an “overweight” rating and issued a $12.00 price objective on shares of Sana Biotechnology in a report on Friday, March 13th. Bank of America increased their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a report on Tuesday. Finally, Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.20.

Sana Biotechnology Stock Down 1.1%

The company has a fifty day moving average of $3.48 and a two-hundred day moving average of $4.13. The stock has a market capitalization of $918.03 million, a price-to-earnings ratio of -3.55 and a beta of 2.06.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03). Equities analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

Several hedge funds have recently modified their holdings of SANA. Wealth Enhancement Advisory Services LLC lifted its holdings in Sana Biotechnology by 4.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock valued at $188,000 after acquiring an additional 2,023 shares during the period. Xponance LLC lifted its holdings in Sana Biotechnology by 25.6% in the fourth quarter. Xponance LLC now owns 13,068 shares of the company’s stock valued at $53,000 after acquiring an additional 2,662 shares during the period. Creative Planning lifted its holdings in Sana Biotechnology by 5.3% in the third quarter. Creative Planning now owns 54,177 shares of the company’s stock valued at $192,000 after acquiring an additional 2,719 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Sana Biotechnology by 29.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock valued at $53,000 after acquiring an additional 2,943 shares during the period. Finally, Savant Capital LLC lifted its holdings in Sana Biotechnology by 5.6% in the third quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock valued at $236,000 after acquiring an additional 3,500 shares during the period. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.